Delta-Fly Pharma, Inc. (JP:4598)
:4598
Want to see JP:4598 full AI Analyst Report?
4598 Stock Chart & Stats
¥507.00
-¥3.00(-0.55%)
At close: 4:00 PM EST
¥507.00
-¥3.00(-0.55%)
Day’s Range― - ―
52-Week Range¥142.00 - ¥793.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)379.72K
Market Cap
¥2.09B
Enterprise Value¥1.95B
Total Cash (Recent Filing)¥730.32M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-171.79
Shares Outstanding14,225,000
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure removes fixed interest obligations and lowers short-term default risk, giving management flexibility to prioritize R&D and negotiate partnerships. For a development-stage biotech this durable feature reduces insolvency risk and preserves options for equity or partnership financing.
Proprietary Drug Delivery & Oncology FocusOwning proprietary delivery technology and focusing on oncology creates structural competitive advantages: improved therapeutic differentiation, higher licensing value, and barriers to entry. In oncology, persistent unmet needs support multi-year commercial potential if clinical development succeeds.
Access To Partnership/grant FundingEstablished pathways for strategic collaborations, milestone payments, and grants provide diversified, often non-dilutive or milestone-linked capital. Over a multi-month horizon these funding channels can extend clinical runway, align incentives with larger partners, and reduce reliance on immediate equity issuance.
Bears Say
No Revenue Since FY2023Absence of product revenue for multiple years means the company generates no internal cash to fund operations or scale development programs. This structural lack of operating income makes long-term viability contingent on successful clinical outcomes and continued external financing.
Widening Net LossesPersistently negative and worsening net income increases cumulative funding needs and erodes retained capital. Over the coming months this trend heightens dependency on dilutive financing or partner funding and constrains the firm's ability to invest concurrently across multiple development programs.
Severe Cash Burn And Eroded Equity/assetsSustained negative operating and free cash flows alongside a collapse in equity and assets materially reduce financial flexibility. This shrinking balance sheet increases fundraising frequency and dilution risk, weakens bargaining power in partnerships, and could force program delays if new capital isn't secured.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥142.00 and its highest was ¥793.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥2.09B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 62 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on May 15, 2026. The company reported -¥29.73 earnings per share for the quarter, missing the consensus estimate of N/A by -¥29.73.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 14,225,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥29.73 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.